MIKAYLA BALLARD: Open Payments
NPI 1770358780 · LITTLE ROCK, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,352 in 59 payments from 16 companies in 2025. Trend: 2023 $120 · 2024 $830 · 2025 $1,352
Food & beverage: $1,352
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 15 | $471 |
| ViiV Healthcare Company | 10 | $142 |
| Neurocrine BioSciences, Inc. | 5 | $115 |
| ABBVIE INC. | 5 | $107 |
| Vanda Pharmaceuticals Inc. | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| EMD Serono, Inc. | 2 | $62 |
| Alkermes, Inc. | 3 | $52 |
| Indivior Inc. | 1 | $32 |
Products named: Biktarvy, DOVATO, INGREZZA, Yeztugo, VRAYLAR, CAPLYTA, REXULTI, FANAPT.
Industry payments across AR — which companies pay providers there.
